Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.
Villejuif, France. In N Engl J Med, Dec 2015
BACKGROUND: Cabozantinib is an oral, small-molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR) as well as MET and AXL, each of which has been implicated in the pathobiology of metastatic renal-cell carcinoma or in the development of resistance to antiangiogenic drugs.
Mechanisms of resistance to EGFR tyrosine kinase inhibitors.
Guangzhou, China. In Acta Pharm Sin B, Sep 2015
Resistance to EGFR-TKIs is inevitable due to various mechanisms, such as the secondary mutation (T790M), activation of alternative pathways (c-Met, HGF, AXL), aberrance of the downstream pathways (K-RAS mutations, loss of PTEN), impairment of the EGFR-TKIs-mediated apoptosis pathway (BCL2-like 11/BIM deletion polymorphism), histologic transformation, ATP binding cassette (ABC) transporter effusion, etc.
Cell Death in C. elegans Development.
New York City, United States. In Curr Top Dev Biol, 2014
A core pathway consisting of the conserved proteins EGL-1/BH3-only, CED-9/BCL2, CED-4/APAF1, and CED-3/caspase promotes most cell death in the nematode, and a conserved set of proteins ensures the engulfment and degradation of dying cells.
Role of DNA methylation in renal cell carcinoma.
United States. In J Hematol Oncol, 2014
In particular, members of the Wnt and TGF-beta pathways, pro-apoptotic genes such as APAF-1 and negative cell-cycle regulators such as KILLIN have been shown to be epigenetically silenced in numerous studies in ccRCC.
TAM receptor signaling in immune homeostasis.
In Annu Rev Immunol, 2014
The TAM receptor tyrosine kinases (RTKs)-TYRO3, AXL, and MERTK-together with their cognate agonists GAS6 and PROS1 play an essential role in the resolution of inflammation.